TSLA
Tesla
-- 278.390 NVDA
NVIDIA
-- 121.410 AMD
Advanced Micro Devices
-- 113.850 PLTR
Palantir
-- 96.750 MLGO
MicroAlgo
-- 13.990 
UPDATES
$Immutep (IMMP.US)$
Immutep (IMMP) announces the presentation of new data from EFTISARC-NEO, a Phase II investigator-initiated trial of eftilagimod alpha in combination with radiotherapy plus KEYTRUDA for patients with soft tissue sarcoma, STS, at the Connective Tissue Oncology Society, CTOS, 2024 Annual Meeting. Based on preliminary analysis among 21 patients available for primary endpoint assessment, the triple combination therapy demonstrates significant efficacy in the neoadjuvant setting for resectable STS.
Immutep (IMMP) announces the presentation of new data from EFTISARC-NEO, a Phase II investigator-initiated trial of eftilagimod alpha in combination with radiotherapy plus KEYTRUDA for patients with soft tissue sarcoma, STS, at the Connective Tissue Oncology Society, CTOS, 2024 Annual Meeting. Based on preliminary analysis among 21 patients available for primary endpoint assessment, the triple combination therapy demonstrates significant efficacy in the neoadjuvant setting for resectable STS.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment